Marco Ulises Martínez-Martínez1,2, David Alejandro Herrera-van Oostdam1,3, Carlos Abud-Mendoza4. 1. Faculty of Medicine, Universidad Autónoma San Luis Potosí and Hospital Central "Dr. Ignacio Morones Prieto", Avenida Venustiano Carranza 2395, Zona Universitaria, 78290, San Luis Potosí, San Luis Potosí, Mexico. 2. Hospital General de Zona No. 1, Instituto Mexicano del Seguro Social, San Luis Potosí, San Luis Potosí, Mexico. 3. Hospital General de Zona No. 50, Instituto Mexicano del Seguro Social, San Luis Potosí, San Luis Potosí, Mexico. 4. Faculty of Medicine, Universidad Autónoma San Luis Potosí and Hospital Central "Dr. Ignacio Morones Prieto", Avenida Venustiano Carranza 2395, Zona Universitaria, 78290, San Luis Potosí, San Luis Potosí, Mexico. c_abud@hotmail.com.
Abstract
PURPOSE OF REVIEW: The present paper establishes a narrative and analytical review of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus erythematosus, and antiphospholipid syndrome. RECENT FINDINGS: Recent studies found a frequent association between DAH and infections and systemic lupus erythematosus and its associated factors. Biological therapies like rituximab have demonstrated benefit mainly in patients with ANCA-associated vasculitis. Main clinical manifestations of diffuse alveolar hemorrhage in these three diseases include dyspnea, pulmonary infiltrates, cough, and hypoxemia. The presence of hemorrhagic bronchoalveolar lavage, hemosiderin containing macrophages, or an increase of carbon monoxide diffusing capacity have been described in some series as helpful findings for the diagnosis. Hemoptysis has been seen mainly in systemic lupus erythematosus. The cornerstone of therapy includes glucocorticoids and cyclophosphamide, and recent findings in ANCA-associated vasculitis suggest the similar benefit of rituximab. Future evaluations and systematic reviews will help to define the real benefit for therapies that appeared to be controversial at the moment.
PURPOSE OF REVIEW: The present paper establishes a narrative and analytical review of diffuse alveolar hemorrhage (DAH) in ANCA-associated vasculitis, systemic lupus erythematosus, and antiphospholipid syndrome. RECENT FINDINGS: Recent studies found a frequent association between DAH and infections and systemic lupus erythematosus and its associated factors. Biological therapies like rituximab have demonstrated benefit mainly in patients with ANCA-associated vasculitis. Main clinical manifestations of diffuse alveolar hemorrhage in these three diseases include dyspnea, pulmonary infiltrates, cough, and hypoxemia. The presence of hemorrhagic bronchoalveolar lavage, hemosiderin containing macrophages, or an increase of carbon monoxide diffusing capacity have been described in some series as helpful findings for the diagnosis. Hemoptysis has been seen mainly in systemic lupus erythematosus. The cornerstone of therapy includes glucocorticoids and cyclophosphamide, and recent findings in ANCA-associated vasculitis suggest the similar benefit of rituximab. Future evaluations and systematic reviews will help to define the real benefit for therapies that appeared to be controversial at the moment.
Authors: Philip J Klemmer; W Chalermskulrat; Michael S Reif; Susan L Hogan; David C Henke; Ronald J Falk Journal: Am J Kidney Dis Date: 2003-12 Impact factor: 8.860
Authors: Anne Angelillo-Scherrer; Behrouz Mansouri Taleghani; Frauke Förger; Gabriela M Baerlocher; Thomas Pabst; Alexander Pöllinger; Yara Banz; Thomas Geiser; Johanna A Kremer Hovinga; Alicia Rovó Journal: Blood Adv Date: 2019-09-10
Authors: Pui Y Lee; Nathan Nelson-Maney; Yuelong Huang; Anaïs Levescot; Qiang Wang; Kevin Wei; Pierre Cunin; Yi Li; James A Lederer; Haoyang Zhuang; Shuhong Han; Edy Y Kim; Westley H Reeves; Peter A Nigrovic Journal: JCI Insight Date: 2019-08-08
Authors: Illaa Smesseim; Titia Schaepman-Ruys; Jan Willem Duitman; Yosta Vegting; Jorinde Raasveld; Marc Hilhorst; Alexander Vlaar; Josien van Es; Peter Bonta Journal: J Crit Care Med (Targu Mures) Date: 2022-05-12
Authors: Jae Won Kim; Tae Woo Kim; Keon Hee Ryu; Sun Gyoo Park; Chang Young Jeong; Dong Ho Park Journal: J Int Med Res Date: 2020-01 Impact factor: 1.671